Valuation: Novartis AG

Market Cap 289B 250B 235B 214B 402B 27,678B 408B 2,753B 1,076B 13,860B 1,087B 1,063B 46,059B P/E 2026 *
21.6x
P/E 2027 * 18.5x
Enterprise Value 323B 279B 262B 238B 448B 30,844B 455B 3,067B 1,199B 15,446B 1,211B 1,185B 51,328B EV / Sales 2026 *
5.6x
EV / Sales 2027 * 5.19x
Free-Float
91.66%
Yield 2026 *
2.87%
Yield 2027 * 2.99%
1 day-0.98%
1 week-1.39%
Current month-2.64%
1 month-1.86%
3 months+3.95%
6 months-3.66%
Current year+11.72%
1 week 128.92
Extreme 128.92
136.26
1 month 128.92
Extreme 128.92
140.82
Current year 116
Extreme 116
144.12
1 year 103.16
Extreme 103.16
144.12
3 years 94
Extreme 94
144.12
5 years 94
Extreme 94
144.12
10 years 61.7
Extreme 61.7
144.12
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Compliance Officer 58 2025-04-13
Director TitleAgeSince
Director/Board Member 67 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.98%-1.39% - - 289B
-2.25%-0.99%+78.68%+123.40% 1,078B
-0.66%+1.31%+49.27%+49.76% 632B
-0.54%+2.29%+23.82%+63.92% 443B
-1.99%-2.63%+42.21%+33.92% 356B
-1.05%-2.19%+25.55%+34.88% 289B
-2.12%-3.29%+0.14%+3.90% 245B
-0.63%+2.56%+43.51%+58.17% 226B
-1.19%+0.37%-9.57%-52.51% 204B
+0.16%+5.73%+15.17%+72.95% 171B
Average -1.07%+1.43%+29.86%+43.15% 404.85B
Weighted average by Cap. -1.26%+1.30%+43.75%+63.35%

Financials

2026 *2027 *
Net sales 57.58B 49.74B 46.74B 42.5B 79.91B 5,506B 81.23B 548B 214B 2,757B 216B 212B 9,163B 61.12B 52.79B 49.61B 45.12B 84.82B 5,845B 86.22B 581B 227B 2,927B 229B 225B 9,726B
Net income 13.78B 11.9B 11.18B 10.17B 19.12B 1,318B 19.44B 131B 51.24B 660B 51.74B 50.62B 2,193B 15.36B 13.26B 12.46B 11.34B 21.31B 1,469B 21.66B 146B 57.1B 735B 57.66B 56.41B 2,444B
Net Debt 33.11B 28.6B 26.88B 24.44B 45.95B 3,166B 46.71B 315B 123B 1,586B 124B 122B 5,269B 27.82B 24.03B 22.58B 20.53B 38.6B 2,660B 39.24B 265B 103B 1,332B 104B 102B 4,426B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
26-08-12 132.10 -0.72% 2,795
26-08-14 €130.44 -1.26% 2,054
26-08-13 €132.10 -0.72% 2,795
26-08-12 €133.06 -1.20% 1,476
26-08-11 €134.68 -0.72% 2,155
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
150.86USD
Average target price
154.18USD
Spread / Average Target
+2.20%

Quarterly revenue - Rate of surprise